# Safety and Efficacy Trial of DNA Vaccines to Treat Genital Herpes in Adults

> **NCT02030301** · PHASE1,PHASE2 · COMPLETED · sponsor: **Vical** · enrollment: 165 (actual)

## Conditions studied

- Genital Herpes Simplex Type 2

## Interventions

- **BIOLOGICAL:** VCL-HB01
- **BIOLOGICAL:** VCL-HM01
- **BIOLOGICAL:** PBS

## Key facts

- **NCT ID:** NCT02030301
- **Lead sponsor:** Vical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-12
- **Primary completion:** 2015-06
- **Final completion:** 2016-02
- **Target enrollment:** 165 (ACTUAL)
- **Last updated:** 2019-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02030301

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02030301, "Safety and Efficacy Trial of DNA Vaccines to Treat Genital Herpes in Adults". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02030301. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*